Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Boost for biotech sector as two UK-listed names receive premium bids
Thursday 05 Nov 2020 Author: Martin Gamble

The  announcement of second lockdown measures in England gave biotechnology shares involved in Covid-19 testing another a boost with Avacta (AVCT:AIM), Omega Diagnostics (ODX:AIM), Genedrive (GDR:AIM) all registering gains.

However these moves were overshadowed by the 110% gain in gene cell engineering company [bold] Horizon Discovery (HZD:AIM) and the 75% gain in blood flow monitoring firm LiDCO (LID:AIM) which both received takeover offers. The premiums offered in these transactions suggests the industry sees the market as undervaluing some biotech firms.

Horizon Discovery shareholders received an all-cash offer of 185p per share cash offer worth £296 million, representing a 108.3% premium to the closing price on 30 October of 88.8p. The directors of Horizon unanimously recommended the offer.

The buyer is US based life science firm [bold] PerkinElmer which generates revenues of $3.4 billion and has a market capitalisation of $14.4 billion. The company said it had received acceptance from 21.1% of Horizon’s shareholders.

Meanwhile LiDCO shareholders received an all-cash offer of 12p per share from Masimo Corporation, valuing the company at £31.1 million and representing a 77.8% premium to a 30 October closing price of 6.75p. The board have recommended the offer with Masimo having garnered agreement from 37.7% of LiDCO’s shareholders.

Masimo is a Nasdaq listed global medical technology company with a market capitalisation of $12 billion.

‹ Previous2020-11-05Next ›